Inside U.S. Generic Drug Approvals: Risk, Regulation & Policy w/ Jennifer Kao

Episode notes

In this episode, Rob Lott interviews Jennifer Kao of the UCLA Anderson School of Management in front of a live audience about her paper in the October 2025 issue of Health Affairs exploring the impact of risk evaluation and mitigation strategies on generic approvals of US pharmaceutical products. Order the October 2025 issue of Health Affairs . Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support , we can continue to keep our digital publication Forefront and podcast for everyone.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Why Mega Healthcare is Hard to DisruptProduct in Healthtech · on big pharma
• The Ongoing Burden of Specialty Drugs - What Drives It and What You Can Do About It - Janet YoungHealthcare on the Rocks · on generic drugs

• Health Care Acquisitions: What Happens to Patient Care Intensity?91 / 100
• How ACO Conveners Are Changing the Medicare Shared Savings Program (MSSP) Behind the Scenes82 / 100
• Why Medicare’s Hospital Wage Index Exceptions Jumped 60%85 / 100
• Private Equity in Primary Care: Costs, Care, and Impact90 / 100
• Inside CMS: How Medicare Innovation Models Are Working to Lower Costs & Scale Digital Health88 / 100